Views & Analysis

Views & Analysis
Almirall looks for action in eczema

Almirall gets in on the eczema action

Sanofi’s Dupixent has shown there is a market for biologic drugs to treat eczema, and now Spain’s Almirall wants a piece of the action.

Views & Analysis
Who will pay the price for inaction on superbugs

Who will pay the price for inaction on superbugs?

While the UK government has been applauded for its efforts in raising awareness about antimicrobial resistance, its efforts to convince pharma to invest in new antibiotics have so far been

Views & Analysis
NICE

NICE numbers at 20

Leela Barham takes a look at NICE’s stats on Technology Appraisals to see how the agency has changed over it’s 20-year history and what the future might hold.

Views & Analysis
Optimising market access for biosimilars

Optimising market access for biosimilars

We speak to Sandoz’s global head of biopharmaceuticals, Stefan Hendriks, about the remaining challenges in market access for biosimilars and what the future could hold for this still-bu